Foundry Partners LLC Has $463,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Foundry Partners LLC increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,162 shares of the specialty pharmaceutical company’s stock after purchasing an additional 381 shares during the period. Foundry Partners LLC owned approximately 0.05% of Collegium Pharmaceutical worth $463,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COLL. JPMorgan Chase & Co. raised its holdings in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at $2,432,000. Principal Financial Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Collegium Pharmaceutical by 593.7% in the 4th quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company’s stock valued at $1,923,000 after purchasing an additional 57,455 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Collegium Pharmaceutical by 399.4% in the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock worth $2,686,000 after purchasing an additional 55,572 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $28.14 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm has a market capitalization of $904.19 million, a price-to-earnings ratio of 12.13 and a beta of 0.76. The firm’s 50 day moving average is $30.02 and its 200-day moving average is $32.16. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on COLL. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Friday, January 10th. Finally, Piper Sandler dropped their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $43.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Colleen Tupper sold 977 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. This trade represents a 0.59 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,193 shares of company stock worth $3,243,594. Company insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.